Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00779883 · ClinicalTrials.gov registry record · Phase 1
A Phase I Trial of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35)
A Phase 1 study, sponsored by Memgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT00779883: Completed Phase 1 study, sponsored by Memgen.
NCT00779883 is a Phase 1 study that has completed, run by Memgen. The registered enrollment target is 9 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00779883, a Phase 1 study, has completed, sponsored by Memgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
The study is a Phase I, dose-escalating, non-randomized, single institution clinical trial assessing the safety and efficacy of autologous Ad-ISF35-transduced CLL B cells administered as a single intravenous infusion in patients with chronic lymphocytic leukemia (CLL).
Interventions
- BIOLOGICAL ISF35
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2006-06 |
| Est. Completion | 2008-03 |
| Phase | Phase 1 |
What the finished NCT00779883 record still lists
NCT00779883 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 1 intervention - of which ISF35 is the first listed.
NCT00779883 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00779883 about?
NCT00779883 is a clinical study titled "A Phase I Trial of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35)". The study is a Phase I, dose-escalating, non-randomized, single institution clinical trial assessing the safety and efficacy of autologous Ad-ISF35-transduced CLL B cells administered as a single intravenous infusion in patients with chronic lymphocytic leukemia (CLL).
What is the current status of trial NCT00779883?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2006-06. Estimated completion is 2008-03.
What interventions are being tested in trial NCT00779883?
The interventions under investigation include: ISF35 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00779883?
This trial is sponsored by Memgen, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00779883's enrollment target sits among peer trials
9 1955th of 2000 higher than 42 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia